An observational study in Cystic Fibrosis, sponsored by Hospices Civils de Lyon. Recruiting at 3 sites in France. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-09-20.
Sponsored by Hospices Civils de Lyon · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Cystic Fibrosis by Hospices Civils de Lyon — 10 open to participants now, 11 under way, none of them phase 3. Cystic Fibrosis · Hospices Civils de Lyon.
Among the 35 studies in Cystic Fibrosis by Hospices Civils de Lyon, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2024, is one of 22 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 31st registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →10 of the 35 studies in Cystic Fibrosis by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 2–17
Hospices Civils de Lyon · Sites in France
Ages 18–65
Hospices Civils de Lyon · Sites in France
Ages 10+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6+
Hospices Civils de Lyon · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 180 is above the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 38 across the 13 interventional studies, 160 across the 22 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
2 of the studies in Cystic Fibrosis by Hospices Civils de Lyon that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06599892Hospices Civils de LyonCF Organization of Care in the Era of Highly Effective Modulator. | 2026-12-31 |
| NCT07303621Hospices Civils de LyonPopulation Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population | 2027-08-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Cystic Fibrosis by Hospices Civils de Lyon, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cystic fibrosis (CF) is a rare disease affecting one out of 4,500 newborns in France (INSERM 2021). Despite major advances in patient care over the past two decades, with significant improvements in life expectancy, cystic fibrosis remains a pathology that considerably impairs quality of life.
Several studies have reported the possibility of respiratory and non-respiratory sleep disorders (SD) in patients with CF. Respiratory disorders are reported to affect 30% of children with CF (Barbosa 2020). Among non-respiratory SD, sleep onset and maintenance insomnia are well known in these patients, while chronotype abnormalities (circadian rhythm disorders) are understudied. Chronotype refers to a person's tendency to be more efficient in the morning or evening.
The existence of chronotype abnormalities has been suggested in CF patients, but no precise data are available (Louis 2022). The involvement of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein dysfunction in the central nervous system (CNS) has been hypothesized as a contributory factor. In vivo, in a mouse model of CF, dysregulation of clock genes such as Clock, Cry2 and Per2 was found in the CNS (Barbato 2019). Among them, certain genes such as Rev-erbα could regulate endobronchial inflammation and contribute to the severity of respiratory pathology. All in all, chronotype abnormalities could be at the origin of sleep debt, impaired cognitive functions or metabolic disturbances.
In the era of highly effective modulator therapy (HEMT) for the treatment of CF, the impact of these new therapies on chronotype has been understudied. Assuming that chronotype abnormalities are a direct consequence of CFTR protein dysfunction in the retina and anterior hypothalamus, HEMT should improve sleep quality. However, between 20% and 30% of adult and pediatric patients express an increase in chronotype abnormalities following initiation of treatment.
Paradoxically, the perceived gain in respiratory quality of life is counterbalanced by the occurrence of these disorders. Some patients would effectively reverse their treatment in order to limit the phenomenon. A single polysomnographic study evaluated the effect of HEMT Kaftrio-Kalydeco on sleep in adults with CF (Welsner 2022). After 3 months of treatment, patients had a significant reduction in respiratory events, with no change in total sleep time, sleep efficiency or sleep architecture. Chronotype was not mentioned. Currently, no studies on chronotype in children or adults with CF have been carried out. Our hypothesis is that CF patients treated with HEMT would develop an abnormal chronotype of late sleep onset.
The aim of this study is to evaluate the chronotype of children with CF treated with HEMT. Chronotype abnormalities could have major consequences for quality of life, the immune system, cognitive functions and metabolism. Systematic detection of these disorders via anamnesis, followed by diagnosis by questionnaire, actimetrics and/or urinary melatonin dosage, would enable their early management, starting with the reversal of Kaftrio-Kalydeco intake between morning and evening.
Patients will be selected from Cystic Fibrosis Resource and Skill Centres of pediatric tertiary care hospitals (Lyon, Paris-Trousseau, Nancy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with cystic fibrosis Aged from 2 to 17 years and 11 months Treated with CFTR modulator Kaftrio-Kalydeco for at least 2 months Followed in a participating Cystic Fibrosis Resource and Skill national Centre
Result of the Horne and Ostberg questionnaire.
The frequency of each chronotype (normal, morning or evening) in patients with CF on HEMT will be determined by the result of the Horne and Ostberg questionnaire. The frequency of each chronotype will be summarized for all CF patients on HEMT using the following descriptive statistics: frequencies and percentages for each level of the variable (normal, morning or evening) and the number of missing values (missing values will be counted but not included in the denominator of the frequency calculation). Scores from 5 to 25: 21-25 = clearly morning; 18-20 = moderately morning; 12-17 = nor morning, neither evening; 9-11: moderately evening; 5-8: clearly evening.
Time frame: Day 0
Started Apr 2024 (actual). Primary completion is estimated for Oct 2025, 18 months after the start.
Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 18 months is below that.
Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.